NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Wang Y, Zhao S. Vascular Biology of the Placenta. San Rafael (CA): Morgan & Claypool Life Sciences; 2010.

Cover of Vascular Biology of the Placenta

Vascular Biology of the Placenta.

Show details


  1. Ellery PM, Cindrova-Davies T, Jauniaux E, Ferguson-Smith AC, Burton GJ. Evidence for transcriptional activity in the syncytiotrophoblast of the human placenta. Placenta. 2009;30(4):329–334.10.1016/j.placenta.2009.01.002. [PMC free article: PMC3712185] [PubMed: 19215981] [Cross Ref]
  2. Jackson MR, Mayhew TM, Boyd PA. Quantitative description of the elaboration and maturation of villi from 10 weeks of gestation to term. Placenta. 1992;13(4):357–370.10.1016/0143-4004(92)90060-7. [PubMed: 1438084] [Cross Ref]
  3. Lang I, Pabst MA, Hiden U, Blaschitz A, Dohr G, Hahn T, Desoye G. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol. 2003;82(4):163–173.10.1078/0171-9335-00306. [PubMed: 12751902] [Cross Ref]
  4. Burrows TD, King A, Loke YW. Trophoblast migration during human placental implantation. Hum Reprod Update. 1996;2(4):307–321. [PubMed: 9080228]
  5. Meekins JW, Luckas MJM, Pijnenborg R, McFadyen IR. Histological study of decidual spiral arteries and the presence of maternal erythrocytes in the intervillous space during the first trimester of normal human pregnancy. Placenta. 1997;18:459–464.10.1016/S0143-4004(97)80048-3. [PubMed: 9250710] [Cross Ref]
  6. Jaffe R, Jauniaux E, Hustin J. Maternal circulation in the first-trimester human placenta—myth or reality? Am J Obstet Gynecol. 1997;176(3):695–705.10.1016/S0002-9378(97)70572-6. [PubMed: 9077631] [Cross Ref]
  7. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III LC, Wenstrom KD. Chapter 3. Implantation, embryogenesis, and placental development. Williams Obstetrics, 22nd Edition 2005:39–90.
  8. Gowland PA, Francis ST, Duncan KR, Freeman AJ, Issa B, Moore RJ, Bowtell RW, Baker PN, Johnson IR, Worthington BS. In vivo perfusion measurements in the human placenta using echo planar imaging at 0.5 T. Magn Reson Med. 1998;40(3):467–473.10.1002/mrm.1910400318. [PubMed: 9727951] [Cross Ref]
  9. Benirschke K, Kaufmann P, Baergen R. Chapter 12. Anatomy and pathology of the umbilical cord. Pathology of the human placenta. 5th Edition. Ed: Benirschke K, Kaufmann P, Baergen R. 2006:380–451.
  10. Harold JG, Siegel RJ, FitzGerald GA, Satoh P, Fishbein MC. Differential prostacyclin production by human umbilical vasculature. Arch Pathol Lab Med. 1988;112(1): 43–46. [PubMed: 3276285]
  11. Karbowski B, Bauch HJ, Schneider HP. Functional differentiation of umbilical vein endothelial cells following pregnancy complicated by smoking or diabetes mellitus. Placenta. 1991;12:405.
  12. Giles W, O’Callaghan S, Read M, Gude N, King R, Brennecke S. Placental nitric oxide synthase activity and abnormal umbilical artery flow velocity waveforms. Obstet Gynecol. 1997;89(1):49–52.10.1016/S0029-7844(96)00371-7. [PubMed: 8990436] [Cross Ref]
  13. El Behery MM, Nouh AA, Alanwar AM, Diab AE. Effect of umbilical vein blood flow on perinatal outcome of fetuses with lean and/or hypo-coiled umbilical cord. Arch Gynecol Obstet. 2009 Nov 7. [Epub ahead of print].10.1007/s00404-009-1272-0. [PubMed: 19898858] [Cross Ref]
  14. Castellucci M, kaufmann P. Chapter 7. Architecture of naormal villous trees. Pathology of the human placenta. 5th Edition. Ed: Benirschke K, Kaufmann P, Baergen R. 2006, 121–173.
  15. Castellucci M, Scheper M, Scheffen I, Celona A, Kaufmann P. The development of the human placental villous tree. Anat Embryol. (Berl). 1990;181(2):117–128.10.1007/BF00198951. [PubMed: 2327595] [Cross Ref]
  16. Castellucci M, Kosanke G, Verdenelli F, Huppertz B, Kaufmann P. Villous sprouting: fundamental mechanisms of human placental development. Hum Reprod Update. 2000; 6(5):485–494.10.1093/humupd/6.5.485. [PubMed: 11045879] [Cross Ref]
  17. Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development puzzle. Science. 1994;266:1508–1518.10.1126/science.7985020. [PubMed: 7985020] [Cross Ref]
  18. Crocker IP, Strachan BK, Lash GE, Cooper S, Warren AY, Baker PN. Vascular endothelial growth factor but not placental growth factor promotes trophoblast syncytialization in vitro. J Soc Gynecol Investig. 2001;8:341–346. [PubMed: 11750869]
  19. Nelson DM, Crouch EC, Curran EM, Farmer DR. Trophoblast interaction with fibrin matrix. Am J Pathol. 1990;136:855–865. [PMC free article: PMC1877640] [PubMed: 2327472]
  20. Torry DS, Ahn H, Barnes EL, Torry RJ. Placenta growth factor: potential role in pregnancy. Am J Reprod Immunol. 1999;41:79–85. [PubMed: 10097790]
  21. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Ann. 1972;1:177–191. [PubMed: 4669123]
  22. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol. 1967;93:581–592.10.1002/path.1700930219. [PubMed: 6054058] [Cross Ref]
  23. DeWolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol. 1975;123:164–174. [PubMed: 1163579]
  24. Burton GJ, Woods AW, Jaunlaux E, Kingdom JCP. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009;30(6):473–482.10.1016/j.placenta.2009.02.009. [PMC free article: PMC2697319] [PubMed: 19375795] [Cross Ref]
  25. Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel). 1989;136(3):190–203.10.1159/000146886. [PubMed: 2481376] [Cross Ref]
  26. Hofbauer J. Uber das konstante vorkommen bisher unbekannter zelliger Formelemente in der Chorionzotte der menschlichen Plazenta und uber Embryotrophe. Wien. Klin. Wochenschr. 1903;16:871–873.
  27. Khan S, Katabuchi H, Araki M, Nishimura R, Okamura H. Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro. Biol Reprod. 2000;62(4):1075–1083.10.1095/biolreprod62.4.1075. [PubMed: 10727280] [Cross Ref]
  28. Cooper JC, Sharkey AM, McLaren J, Charnock-Jones DS, Smith SK. Localization of vascular endothelial growth factor and its receptor, flt, in human placenta and decidua by immunohistochemistry. J Reprod Fertil. 1995;105(2):205–213.10.1530/jrf.0.1050205. [PubMed: 8568762] [Cross Ref]
  29. Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, Rollason T. Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors. 1995;12(3):235–243.10.3109/08977199509036883. [PubMed: 8619929] [Cross Ref]
  30. Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, Huppertz B. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta. 2004;25(6):560–572.10.1016/j.placenta.2003.11.011. [PubMed: 15135240] [Cross Ref]
  31. Seval Y, Korgun ET, Demir R. Hofbauer cells in early human placenta: possible implications in vasculogenesis and angiogenesis. Placenta. 2007;28(8-9):841–845.10.1016/j.placenta.2007.01.010. [PubMed: 17350092] [Cross Ref]
  32. Anteby EY, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Haimov-Kochman R, Holzer H, Yagel S. Human placental Hofbauer cells express sprouty proteins: a possible modulating mechanism of villous branching. Placenta. 2005;26(6):476–483.10.1016/j.placenta.2004.08.008. [PubMed: 15950061] [Cross Ref]
  33. Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis. 2008;11(1):53–62.10.1007/s10456-008-9089-1. [PubMed: 18219583] [Cross Ref]
  34. Natanson-Yaron S, Anteby EY, Greenfield C, Goldman-Wohl D, Hamani Y, Hochner-Celnikier D, Yagel S. FGF 10 and Sprouty 2 modulate trophoblast invasion and branching morphogenesis. Mol Hum Reprod. 2007;13(7):511–519.10.1093/molehr/gam034. [PubMed: 17496316] [Cross Ref]
  35. Sims DE. Diversity within pericytes. Clin Exp Pharmacol Physiol 2000;27:842–846.10.1046/j.1440-1681.2000.03343.x. [PubMed: 11022980] [Cross Ref]
  36. Hirschi KK, D’Amore PA. Pericytes in the microvasculature. Cardiovasc Res. 1996;32: 687–698. [PubMed: 8915187]
  37. Challier JC, Kacemi A, Olive G. Mixed culture of pericytes and endothelial cells from fetal microvessels of the human placenta. Cell Mol Biol. 1995;41(2):233–241. [PubMed: 7787733]
  38. Dye JF, Jablenska R, Donnelly JL, Lawrence L, Leach L, Clark P, Firth JA. Phenotype of the endothelium in the human term placenta. Placenta. 2001;22:32–43.10.1053/plac.2000.0579. [PubMed: 11162350] [Cross Ref]
  39. Lang I, Schweizer A, Hiden U, Ghaffari-Tabrizi N, Hagendorfer G, Bilban M, Pabst MA, Korgun ET, Dohr G, Desoye G. Human fetal placental endothelial cells have a mature arterial and a juvenile venous phenotype with adipogenic and osteogenic differentiation potential. Differentiation. 2008;76(10):1031–1043.10.1111/j.1432-0436.2008.00302.x. [PubMed: 18673379] [Cross Ref]
  40. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992;80(2):283–285. [PubMed: 1635745]
  41. Jauniaux E, Watson A, Burton G. Evaluation of respiratory gases and acid-base gradients in human fetal fluids and uteroplacental tissue between 7 and 16 weeks’ gestation. Am J Obstet Gynecol. 2001;184(5):998–1003.10.1067/mob.2001.111935. [PubMed: 11303211] [Cross Ref]
  42. James JL, Stone PR, Chamley LW. The regulation of trophoblast differentiation by oxygen in the first trimester of pregnancy. Hum Reprod Update. 2006;12(2):137–144. [PubMed: 16234296]
  43. Lyall F, Bulmer JN, Duffie E, Cousins F, Theriault A, Robson SC. Human trophoblast invasion and spiral artery transformation: the role of PECAM-1 in normal pregnancy, preeclampsia, and fetal growth restriction. Am J Pathol. 2001;158(5):1713–1721. [PMC free article: PMC1891950] [PubMed: 11337369]
  44. Genbacev O, Joslin R, Damsky CH , Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest. 1996;97:540–550.10.1172/JCI118447. [PMC free article: PMC507049] [PubMed: 8567979] [Cross Ref]
  45. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997;277:1669–1672.10.1126/science.277.5332.1669. [PubMed: 9287221] [Cross Ref]
  46. Fisher SJ, Roberts JM. Chapter 11. Defects in placentation and placental perfusion. Hypertension in Pregnancy. 2nd Edition. Ed: Lindheimer MD, Roberts JM, Cunningham FG. Stamford, Connecticut: Appleton & Lange; 1999: 377–394.
  47. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99:2152–2164.10.1172/JCI119388. [PMC free article: PMC508045] [PubMed: 9151787] [Cross Ref]
  48. Kingdom JCP, Kaufmann P. Oxygen and placental villous development: Origins of fetal hypoxia. Placenta. 1997;18:613–621.10.1016/S0143-4004(97)90000-X. [PubMed: 9364596] [Cross Ref]
  49. Benirschke K, Kaufmann P, Baergen R. Chapter 15. Classification of villous maldevelopment. Pathology of the human placenta. 5th Edition. Ed: Benirschke K, Kaufmann P, Baergen R. 2006:491–518.
  50. Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem. 2007;109(4):257–265. [PubMed: 17574656]
  51. Demir R, Kayisli UA, Cayli S, Huppertz B. Sequential steps during vasculogenesis and angiogenesis in the very early human placenta. Placenta. 2006;27(6-7):535–539.10.1016/j.placenta.2005.05.011. [PubMed: 16029887] [Cross Ref]
  52. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277 (5322): 48–50.10.1126/science.277.5322.48. [PubMed: 9229772] [Cross Ref]
  53. Ribatti D, Vacca A, Nico B, Ria R, Dammacco F. Cross-talk between hematopoiesis and angiogenesis signaling pathways. Curr Mol Med. 2002;2(6):537–543.10.2174/1566524023362195. [PubMed: 12243246] [Cross Ref]
  54. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 1996;93(6):2576–2581.10.1073/pnas.93.6.2576. [PMC free article: PMC39839] [PubMed: 8637916] [Cross Ref]
  55. Zhou Y, Bellingard V, Feng KT, McMaster M, Fisher SJ. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C. Dev Biol. 2003;263(1):114–125. [PubMed: 14568550]
  56. Vuorela P, Hatva E, Lymboussaki A, Kaipainen A, Joukov V, Persico MG, Alitalo K, Halmesmäki E. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod. 1997;56(2):489–494.10.1095/biolreprod56.2.489. [PubMed: 9116151] [Cross Ref]
  57. Grimmond S, Lagercrantz J, Drinkwater C, Silins G, Townson S, Pollock P, Gotley D, Carson E, Rakar S, Nordenskjöld M and others. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 1996;6(2):124–131.10.1101/gr.6.2.124. [PubMed: 8919691] [Cross Ref]
  58. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(2): 290–298. [PMC free article: PMC449944] [PubMed: 8617204]
  59. Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J Immunol. 2009;182(7):4085–4092.10.4049/jimmunol.0803769. [PMC free article: PMC3616376] [PubMed: 19299706] [Cross Ref]
  60. Leung DW CG, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–1309.10.1126/science.2479986. [PubMed: 2479986] [Cross Ref]
  61. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A. 1991;88(20):9267–9271.10.1073/pnas.88.20.9267. [PMC free article: PMC52695] [PubMed: 1924389] [Cross Ref]
  62. Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta. 2005;25(2–3):210–217. [PubMed: 15708122]
  63. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod. 2008;23(6): 1407–1415.10.1093/humrep/den114. [PubMed: 18413304] [Cross Ref]
  64. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95(2): 548–553.10.1073/pnas.95.2.548. [PMC free article: PMC18457] [PubMed: 9435229] [Cross Ref]
  65. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci U S A. 1996;93(21):11675–11680.10.1073/pnas.93.21.11675. [PMC free article: PMC38117] [PubMed: 8876195] [Cross Ref]
  66. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, Kubo H, Stacker SA, Achen MG. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005;25(6):2441–2449.10.1128/MCB.25.6.2441-2449.2005. [PMC free article: PMC1061605] [PubMed: 15743836] [Cross Ref]
  67. Gu B, Alexander JS, Gu Y, Zhang Y, Lewis DF, Wang Y. Expression of lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1) in the human placenta. Lymphat Res Biol. 2006;4(1):11–17.10.1089/lrb.2006.4.11. [PMC free article: PMC3072054] [PubMed: 16569201] [Cross Ref]
  68. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors. 1993;9(4):259–268.10.3109/08977199308991586. [PubMed: 8148155] [Cross Ref]
  69. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3):215–221.10.1007/s10456-008-9114-4. [PubMed: 18568405] [Cross Ref]
  70. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei KJ, Chou JY, Persico MG. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene. 1993;8(4):925–931. [PubMed: 7681160]
  71. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H, Ahmed A. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors. 1996;13(3-4):243–250. [PubMed: 8919031]
  72. Achen MG, Gad JM, Stacker SA, Wilks AF. Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. Growth Factors. 1997;15(1):69–80.10.3109/08977199709002113. [PubMed: 9401819] [Cross Ref]
  73. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H and others. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575–583. [PubMed: 11329059]
  74. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008;93(1):260–266. [PMC free article: PMC2190747] [PubMed: 17956952]
  75. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88(11):5555–5563.10.1210/jc.2003-030528. [PubMed: 14602804] [Cross Ref]
  76. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE and others. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658. [PMC free article: PMC151901] [PubMed: 12618519]
  77. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH and others. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med. 2004;350(7):672–683.10.1056/NEJMoa031884. [PubMed: 14764923] [Cross Ref]
  78. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R and others. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005. [PubMed: 16957146]
  79. Armelin HA. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci U S A. 1973;70(9):2702–2706.10.1073/pnas.70.9.2702. [PMC free article: PMC427087] [PubMed: 4354860] [Cross Ref]
  80. Gospodarowicz D, Cheng J, Lui GM, Baird A, Böhlent P. Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proc Natl Acad Sci U S A. 1984;81(22):6963–6967.10.1073/pnas.81.22.6963. [PMC free article: PMC392056] [PubMed: 6594674] [Cross Ref]
  81. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature. 1974;249(453):123–127.10.1038/249123a0. [PubMed: 4364816] [Cross Ref]
  82. Olsen SK, Garbi M, Zampieri N, Eliseenkova AV, Ornitz DM, Goldfarb M, Mohammadi M. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem. 2003;278(36):34226–34236.10.1074/jbc.M303183200. [PubMed: 12815063] [Cross Ref]
  83. Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Wed. 2003;9(5):604–613.10.1038/nm848. [PubMed: 12669032] [Cross Ref]
  84. Gospodarowicz D, Cheng J, Lui GM, Fujii DK, Baird A, Böhlen P. Fibroblast growth factor in the human placenta. Biochem Biophys Res Commun. 1985;128(2):554–562.10.1016/0006-291X(85)90082-8. [PubMed: 3994712] [Cross Ref]
  85. Shams M, Ahmed A. Localization of mRNA for basic fibroblast growth factor in human placenta. Growth Factors. 1994;11(2):105–111.10.3109/08977199409001052. [PubMed: 7857655] [Cross Ref]
  86. Ferriani RA, Ahmed A, Sharkey A, Smith SK. Colocalization of acidic and basic fibroblast growth factor (FGF) in human placenta and the cellular effects of bFGF in trophoblast cell line JEG-3. Growth Factors. 1994;10(4):259–268.10.3109/08977199409010992. [PubMed: 7528516] [Cross Ref]
  87. Antebya EY, Natanson-Yarona S, Hamania Y, Sciakia Y, Goldman-Wohla D, Greenfielda C, Arielb I, Yagela S. Fibroblast growth factor-10 and fibroblast growth factor receptors 1–4: expression and peptide localization in human decidua and placenta. Eur J Obstet Gynecol Reprod Biol. 2005; 119(1):27–35.10.1016/j.ejogrb.2004.05.014. [PubMed: 15734081] [Cross Ref]
  88. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC and others. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87(7):1161–1169.10.1016/S0092-8674(00)81812-7. [PubMed: 8980223] [Cross Ref]
  89. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N and others. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277 (5322):55–60.10.1126/science.277.5322.55. [PubMed: 9204896] [Cross Ref]
  90. Seval Y, Sati L, Celik-Ozenci C, Taskin O, Demir R. The distribution of angiopoietin-1, angiopoietin-2 and their receptors tie-1 and tie-2 in the very early human placenta. Placenta. 2008;29(9):809–815.10.1016/j.placenta.2008.06.009. [PubMed: 18675456] [Cross Ref]
  91. Schiessl B, Innes BA, Bulmer JN, Otun HA, Chadwick TJ, Robson SC, Lash GE. Localization of angiogenic growth factors and their receptors in the human placental bed throughout normal human pregnancy. Placenta. 2009;30(1):79–87.10.1016/j.placenta.2008.10.004. [PubMed: 19010534] [Cross Ref]
  92. Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B, Ahmed A. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol. 2000;156(6):2185–2199. [PMC free article: PMC1850068] [PubMed: 10854239]
  93. Cascone I, Audero E, Giraudo E, Napione L, Maniero F, Philips MR, Collard JG, Serini G, Bussolino F. Tie-2-dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood. 2003;102(7):2482–2490.10.1182/blood-2003-03-0670. [PubMed: 12816861] [Cross Ref]
  94. Kim KL, Shin IS, Kim JM, Choi JH, Byun J, Jeon ES, Suh W, Kim DK. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc Res. 2006;72(3):394–402.10.1016/j.cardiores.2006.08.002. [PubMed: 17054925] [Cross Ref]
  95. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D and others. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell. 2002;3(3):411–423.10.1016/S1534-5807(02)00217-4. [PubMed: 12361603] [Cross Ref]
  96. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10(3): 165–177.10.1038/nrm2639. [PubMed: 19234476] [Cross Ref]
  97. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1153–1155. [PubMed: 8980224]
  98. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–248. [PubMed: 11001067]
  99. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70–74.10.1038/376070a0. [PubMed: 7596437] [Cross Ref]
  100. Geva E, Ginzinger DG, Moore DH 2nd, Ursell PC, Jaffe RB. In utero angiopoietin-2 gene delivery remodels placental blood vessel phenotype: a murine model for studying placental angiogenesis. Mol Hum Reprod. 2005;11(4):253–260.10.1093/molehr/gah159. [PubMed: 15734895] [Cross Ref]
  101. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem. 2001;276(28):26516–26525.10.1074/jbc.M100282200. [PubMed: 11346644] [Cross Ref]
  102. Katz AB, Keswani SG, Habli M, Lim FY, Zoltick PW, Midrio P, Kozin ED, Herlyn M, Crombleholme TM. Placental gene transfer: transgene screening in mice for trophic effects on the placenta. Am J Obstet Gynecol. 2009;201(5):499.e1–8.10.1016/j.ajog.2009.06.029. [PMC free article: PMC2885953] [PubMed: 19716119] [Cross Ref]
  103. Myatt L. Current topic: Control of vascular resistance in the human placenta. Placenta. 1992;13:329–341. [PubMed: 1438081]
  104. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000;91(1-3):45–62.10.1016/S0167-0115(00)00138-5. [PubMed: 10967201] [Cross Ref]
  105. Baker PN, Broughton Pipkin F, Symonds EM. Platelet angiotensin II binding and plasma renin concentration, plasma renin substrate and plasma angiotensin II in human pregnancy. Clin Sci. (Lond). 1990;79(4):403–408. [PubMed: 2171863]
  106. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973;52:2682–2689.10.1172/JCI107462. [PMC free article: PMC302534] [PubMed: 4355997] [Cross Ref]
  107. Gant NF, Chand S, Worley RJ, Whalley PJ, Crosby UD, MacDonald PC. A clinical test useful for predicting the development of acute hypertension in pregnancy. Am J Obstet Gynecol. 1974;120:1–7. [PubMed: 4367310]
  108. Gant NF, Worley RJ, Everett RB, MacDonald PC. Control of vascular responsiveness during human pregnancy. Kidney Int. 1980;18(2):253–258.10.1038/ki.1980.133. [PubMed: 6255223] [Cross Ref]
  109. Brosnihan KB, Neves LA, Anton L, Joyner J, Valdes G, Merrill DC. Enhanced expression of Ang-(1-7) during pregnancy. Braz J Med Biol Res. 2004;37(8):1255–1262. [PubMed: 15273828]
  110. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F and others. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;26(277):17.10.1074/jbc.M200581200. [PubMed: 11815627] [Cross Ref]
  111. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D and others. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945–952.10.1172/JCI4106. [PMC free article: PMC408252] [PubMed: 10194466] [Cross Ref]
  112. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H and others. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101: 2382–2387. [PubMed: 10821814]
  113. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J and others. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632–1639.10.1161/01.CIR.0000058200.90059.B1. [PubMed: 12668498] [Cross Ref]
  114. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig. 2003;10:82–93.10.1016/S1071-5576(02)00259-9. [PubMed: 12593997] [Cross Ref]
  115. Hodari AA, Smeby R, Bumpus FM. A renin-like substance in the human placenta. Obstet Gynecol. 1967;29(3):313–317. [PubMed: 4289596]
  116. Ihara Y, Taii S, Mori T. Expression of renin and angiotensinogen genes in the human placental tissues. Endocrinol Jpn. 1987;34(6):887–896. [PubMed: 3330023]
  117. Kalenga MK, Thomas K, de Gasparo M, De Hertogh R. Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension. Clin Endocrinol (Oxf). 1996;44(4): 429–433.10.1046/j.1365-2265.1996.703525.x. [PubMed: 8706309] [Cross Ref]
  118. Anton L, Merrill DC, Neves LA, Diz DI, Corthorn J, Valdes G, Stovall K, Gallagher PE, Moorefield C, Gruver C and others. The uterine placental bed Renin-Angiotensin system in normal and preeclamptic pregnancy. Endocrinology. 2009;150(9):4316–4325.10.1210/en.2009-0076. [PMC free article: PMC2736074] [PubMed: 19520788] [Cross Ref]
  119. Ito M, Itakura A, Ohno Y, Nomura M, Senga T, Nagasaka T, Mizutani S. Possible activation of the renin-angiotensin system in the feto-placental unit in preeclampsia. J Clin Endocrinol Metab. 2002;87(4):1871–1878.10.1210/jc.87.4.1871. [PubMed: 11932332] [Cross Ref]
  120. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension. 2007;49(3):604–611.10.1161/01.HYP.0000257797.49289.71. [PubMed: 17261642] [Cross Ref]
  121. Singh HJ, Rahman A, Larmie ET, Nila A. Raised prorenin and renin concentrations in pre-eclamptic placentae when measured after acid activation. Placenta. 2004;25(7):631–636.10.1016/j.placenta.2004.01.013. [PubMed: 15193869] [Cross Ref]
  122. Anton L, Merrill DC, Neves LA, Stovall K, Gallagher PE, Diz DI, Moorefield C, Gruver C, Ferrario CM, Brosnihan KB. Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension. 2008;51(4):1066–1072.10.1161/HYPERTENSIONAHA.107.103861. [PMC free article: PMC2705753] [PubMed: 18259034] [Cross Ref]
  123. Anton L, Brosnihan KB. Systemic and uteroplacental renin—angiotensin system in normal and pre-eclamptic pregnancies. Ther Adv Cardiovasc Dis. 2008;2 (5):349–362.10.1177/1753944708094529. [PMC free article: PMC2692864] [PubMed: 19124433] [Cross Ref]
  124. Benoit C, Zavecz J, Wang Y. Vasoreactivity of chorionic plate arteries in response to vasoconstrictors produced by preeclamptic placentas. Placenta. 2007;28(5-6):498–504.10.1016/j.placenta.2006.09.002. [PMC free article: PMC3070483] [PubMed: 17070574] [Cross Ref]
  125. Palmer MA, Piper PJ, Vane JR. Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol. 1973;49(2):226–242. [PMC free article: PMC1776376] [PubMed: 4135341]
  126. Yamamoto K, Ebina S, Nakanishi H, Nakahata N. Thromboxane A2 receptor-mediated signal transduction in rabbit aortic smooth muscle cells. Gen Pharmacol. 1995;26(7): 1489–1498.10.1016/0306-3623(95)00025-9. [PubMed: 8690235] [Cross Ref]
  127. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118(1):18–35.10.1016/j.pharmthera.2008.01.001. [PubMed: 18374420] [Cross Ref]
  128. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest. 1996;97(4):949–956.10.1172/JCI118518. [PMC free article: PMC507140] [PubMed: 8613548] [Cross Ref]
  129. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A. 1994;91(2):504–508.10.1073/pnas.91.2.504. [PMC free article: PMC42977] [PubMed: 8290554] [Cross Ref]
  130. Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem. 1991;266(14):9309–9313. [PubMed: 1851174]
  131. Moncada S, Gryglewski RJ, Bunting S, Vane JR. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin x) which prevents platelet aggregation. Prostaglandins. 1976;12: 715–737.10.1016/0090-6980(76)90048-4. [PubMed: 824686] [Cross Ref]
  132. Lafond J, Ayotte N, Brunette MG. Effect of (1-34) parathyroid hormone-related peptide on the composition and turnover of phospholipids in syncytiotrophoblast brush border and basal plasma membranes of human placenta. Mol Cell Endocrinol. 1993;92(2): 207–214.10.1016/0303-7207(93)90010-H. [PubMed: 8391492] [Cross Ref]
  133. Lafond J, Moukdar F, Rioux A, Ech-Chadli H, Brissette L, Robidoux J, Masse A, Simoneau L. Implication of ATP and sodium in arachidonic acid incorporation by placental syncytiotrophoblast brush border and basal plasma membranes in the human. Placenta. 2000;21(7):661–669.10.1053/plac.2000.0561. [PubMed: 10985969] [Cross Ref]
  134. Myatt L, Elder MG. Inhibition of platelet aggregation by a placental substance with prostacyclin-like activity. Nature. 1977;268:159–160.10.1038/268159a0. [Cross Ref]
  135. Walsh SW, Behr MJ, Allen NH. Placental prostacyclin production in normal and toxemic pregnancies. Am J Obstet Gynecol. 1985;151:110–115. [PubMed: 3881024]
  136. Walsh SW. Preeclampsia: An imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol. 1985;152:335–340. [PubMed: 3923838]
  137. Wang Y, Walsh SW, Kay HH. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preeclampsia. Am J Obstet Gynecol. 1992;167: 946–949. [PubMed: 1415430]
  138. Bowen RS, Zhang Y, Gu Y, Lewis DF, Wang Y. Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta. 2005;26:402–409. [PubMed: 15850645]
  139. Wang Y, Walsh SW, Guo J, Zhang J. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am J Obstet Gynecol. 1991;165:1695–1700. [PubMed: 1750462]
  140. Hauth JC, Goldenberg RL, Parker CR, Jr., Phillips JB, Copper RL, DuBard MB, Cutter GR. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol. 1993;168: 1083–1093. [PubMed: 8475955]
  141. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M and others. Low-dose aspirin to prevent preeclampsia in women at high risk. New Engl J Med. 1998;338:701–705. [PubMed: 9494145]
  142. Emeagi J, Patni S, Tikum HM, Mander AM. Low dose aspirin for preventing and treating pre-eclampsia. Author of editorial did not criticise studies’ methodology. BMJ. 1999;319(7205):316. [PMC free article: PMC1126945] [PubMed: 10426756]
  143. Kamio K, Sato T, Liu X, Sugiura H, Togo S, Kobayashi T, Kawasaki S, Wang X, Mao L, Ahn Y and others. Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. Am J Physiol Lung Cell Mol Physiol. 2008;294(6):L1226–1232.10.1152/ajplung.00129.2007. [PubMed: 18424619] [Cross Ref]
  144. Spisni E, Griffoni C, Santi S, Riccio M, Marulli R, Bartolini G, Toni M, Ullrich V, Tomasi V. Colocalization prostacyclin (PGI2) synthase—caveolin-1 in endothelial cells and new roles for PGI2 in angiogenesis. Exp Cell Res. 2001;266(1):31–43.10.1006/excr.2001.5198. [PubMed: 11339822] [Cross Ref]
  145. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M, Ghisdal P, Grégoire V, Dessy C, Balligand JL and others. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res. 2004;95(2):154–161.10.1161/01.RES.0000136344.27825.72. [PubMed: 15205364] [Cross Ref]
  146. Linton EA, Rodriguez-Linares B, Rashid-Doubell F, Ferguson DJ, Redman CW. Caveolae and caveolin-1 in human term villous trophoblast. Placenta. 2003;24(7):745–757.10.1016/S0143-4004(03)00106-1. [PubMed: 12852865] [Cross Ref]
  147. Zhao S, Gu Y, Lewis DF, Wang Y. Predominant basal directional release of thromboxane, but not prostacyclin, by placental trophoblasts from normal and preeclamptic pregnancies. Placenta. 2008;29 (1):81–88.10.1016/j.placenta.2007.08.007. [PMC free article: PMC2235193] [PubMed: 17936899] [Cross Ref]
  148. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.10.1038/332411a0. [PubMed: 2451132] [Cross Ref]
  149. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci. 1989;10(9):374–378. [PubMed: 2690429]
  150. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86(8):485–498.10.1139/Y08-059. [PubMed: 18758495] [Cross Ref]
  151. Wilkes BM, Susin M, Mento PF. Localization of endothelin-1-like immunoreactivity in human placenta. J Histochem Cytochem. 1993;41(4):535–541. [PubMed: 8450193]
  152. Malassiné A, Cronier L, Mondon F, Mignot TM, Ferré F. Localization and production of immunoreactive endothelin-1 in the trophoblast of human placenta. Cell Tissue Res. 1993;271(3):491–497. [PubMed: 8472306]
  153. Barros JS, Bairos VA, Baptista MG, Fagulha JO. Immunocytochemical localization of endothelin-1 in human placenta from normal and preeclamptic pregnancies. Hypertens Pregnancy. 2001;20(1):125–137. [PubMed: 12044321]
  154. Bilban M, Barth S, Cervar M, Mauschitz R, Schaur RJ, Zivkovic F, Desoye G. Differential regulation of endothelin secretion and endothelin receptor mRNA levels in JAR, JEG-3, and BeWo choriocarcinoma cell lines and in human trophoblasts, their nonmalignant counterpart. Arch Biochem Biophys. 2000;382(2):245–252.10.1006/abbi.2000.2016. [PubMed: 11068876] [Cross Ref]
  155. Cervar M, Kainer F, Desoye G. Pre-eclampsia and gestational age differently alter binding of endothelin-1 to placental and trophoblast membrane preparations. Mol Cell Endocrinol. 1995;110(1-2):65–71.10.1016/0303-7207(95)03517-B. [PubMed: 7672454] [Cross Ref]
  156. Cervar M, Puerstner P, Kainer F, Desoye G. Endothelin-1 stimulates the proliferation and invasion of first trimester trophoblastic cells in vitro—a possible role in the etiology of pre-eclampsia? J Investig Med. 1996;44(8):447–453. [PubMed: 8952225]
  157. Wilkes BM, Mento PF, Hollander AM, Maita ME, Sung S, Girardi EP. Endothelin receptors in human placenta: relationship to vascular resistance and thromboxane release. Am J Physiol. 1990;258:E864–E870. [PubMed: 2159236]
  158. Faxén M, Nisell H, Kublickiene KR. Altered gene expression of endothelin-A and endothelin-B receptors, but not endothelin-1, in myometrium and placenta from pregnancies complicated by preeclampsia. Arch Gynecol Obstet. 2000;264(3):143–149. [PubMed: 11129514]
  159. Faxén M, Nasiell J, Lunell NO, Blanck A. Differences in mRNA expression of endothelin-1, c-fos and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia and/or intrauterine growth retardation. Gynecol Obstet Invest. 1997;44(2):93–6. [PubMed: 9286720]
  160. Cervar-Zivkovic M, Hu C, Barton A, Sadovsky Y, Desoye G, Lang U, Nelson DM. Endothelin-1 attenuates apoptosis in cultured trophoblasts from term human placentas. Reprod Sci. 2007;14(5):430–439.10.1177/1933719107305801. [PubMed: 17913962] [Cross Ref]
  161. Buxton IL. Regulation of uterine function: a biochemical conundrum in the regulation of smooth muscle relaxation. Mol Pharmacol. 2004;65(5):1051–1059.10.1124/mol.65.5.1051. [PubMed: 15102932] [Cross Ref]
  162. Tichenor SD, Malmquist NA, Buxton IL. Dissociation of cGMP accumulation and relaxation in myometrial smooth muscle: effects of S-nitroso-N-acetylpenicillamine and 3- morpholinosyndonimine. Cell Signal. 2003;15(8):763–772.10.1016/S0898-6568(03)00006-8. [PubMed: 12781869] [Cross Ref]
  163. Luzi G, Caserta G, Iammarino G, Clerici G, Di Renzo GC. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor. Ultrasound Obstet Gynecol. 1999;14(2):101–109.10.1046/j.1469-0705.1999.14020101.x. [PubMed: 10492869] [Cross Ref]
  164. Sabry S, Mondon F, Ferré F, Dinh-Xuan AT. In vitro contractile and relaxant responses of human resistance placental stem villi arteries of healthy parturients: role of endothelium. Fundam Clin Pharmacol. 1995;9(1):46–51.10.1111/j.1472-8206.1995.tb00264.x. [PubMed: 7768487] [Cross Ref]
  165. Leitch IM, Read MA, Boura AL, Walters WA. Effect of inhibition of nitric oxide synthase and guanylate cyclase on hydralazine-induced vasodilatation of the human fetal placental circulation. Clin Exp Pharmacol Physiol. 1994;21(8):615–622.10.1111/j.1440-1681.1994.tb02562.x. [PubMed: 7529152] [Cross Ref]
  166. Sprague B, Chesler NC, Magness RR. Shear stress regulation of nitric oxide production in uterine and placental artery endothelial cells: experimental studies and hemodynamic models of shear stresses on endothelial cells. Int J Dev Biol. 2010;54(2-3):331–339.10.1387/ijdb.082832bs. [PMC free article: PMC2868123] [PubMed: 19876820] [Cross Ref]
  167. Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in placenta: Evidence of peroxynitrite formation and action. Hypertension. 1996;28:488–493. [PubMed: 8794838]
  168. Norris LA, Higgins JR, Darling MR, Walshe JJ, Bonnar J. Nitric oxide in the uteroplacental, fetoplacental, and peripheral circulations in preeclampsia. Obstet Gynecol. 1999;96(6): 958–963. [PubMed: 10362162]
  169. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, Macconi D, Maucci R, Porrati F, Benigni A and others. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension. 2004;43(3):614–622.10.1161/01.HYP.0000116220.39793.c9. [PubMed: 14744923] [Cross Ref]
  170. Ariel I, Hochberg A, Shochina M. Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease. J Clin Pathol. 1998;51(6):427–431.10.1136/jcp.51.6.427. [PMC free article: PMC500744] [PubMed: 9771440] [Cross Ref]
  171. Barut A, Harma M, Arikan I, Harma MI, Barut F. Endothelial nitric oxide synthase expression in gestational trophoblastic diseases. Int J Gynecol Cancer. 2010;20(3):337–340. [PubMed: 20375793]
  172. Zimmermann K, Opitz N, Dedio J, Renne C, Muller-Esterl W, Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2002;99(26):17167–17172.10.1073/pnas.252345399. [PMC free article: PMC139423] [PubMed: 12446846] [Cross Ref]
  173. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265(36):22348–22357. [PubMed: 2266130]
  174. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102(19):2434–2440. [PubMed: 11067800]
  175. Wang Y, Gu Y, Zhang Y, Lewis DF, Alexander JS, Granger DN. Increased chymotrypsin-like protease (chymase) expression and activity in placentas from women with preeclampsia. Placenta. 2007;28:263–269.10.1016/j.placenta.2006.03.012. [PubMed: 16698079] [Cross Ref]
  176. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991;266:17173–17179. [PubMed: 1894611]
  177. Caughey GH, Zerweck EH, Vanderslice P. Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem. 1991; 266(20):12956–12963. [PubMed: 2071582]
  178. Benoit C, Gu Y, Zhang Y, Alexander JS, Wang Y. Contractility of placental vascular smooth muscle cells in response to stimuli produced by the placenta: roles of ACE vs. non-ACE and AT1 vs. AT2 in placental vessel cells. Placenta. 2008;29(6):503–509.10.1016/j.placenta.2008.03.002. [PMC free article: PMC2556283] [PubMed: 18417209] [Cross Ref]
  179. Lee M, Sommerhoff CP, von Eckardstein A, Zettl F, Fritz H, Kovanen PT. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol. 2002;22(12):2086–2091.10.1161/01.ATV.0000041405.07367.B5. [PubMed: 12482839] [Cross Ref]
  180. Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2002;22(9):1475–1481.10.1161/01.ATV.0000029782.84357.68. [PubMed: 12231569] [Cross Ref]
  181. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med. 1991;174(4):821–825.10.1084/jem.174.4.821. [PMC free article: PMC2118970] [PubMed: 1919436] [Cross Ref]
  182. Pejler G, Rönnberg E, Waern I, Wernersson S. Mast cell proteases- multifaceted regulators of inflammatory disease. Blood. 2010;115(24):4981–4990.10.1182/blood-2010-01-257287. [PubMed: 20233968] [Cross Ref]
  183. Wang Y, Zhang Y, Lewis DF, Gu Y, Li H, Granger DN, Alexander JS. Protease chymotrypsin mediates the endothelial expression of P- and E-selectin, but not ICAM and VCAM, induced by placental trophoblasts from preeclamptic pregnancies. Placenta. 2003;24: 851–861. [PubMed: 13129682]
  184. Zhao S, Gu Y, Fan R, Groome LJ, Cooper D, Wang Y. Proteases and sFlt-1 release in the human placenta. Placenta. 2010; 31:512–518.10.1016/j.placenta.2010.03.014. [PMC free article: PMC3257833] [PubMed: 20434767] [Cross Ref]
  185. Smith CH, Kamath SG. Trophoblast basal and microvillous membrane isolation. Placenta. 1994;15(7):779–781. [PubMed: 7838834]
  186. Boyd CA, Chipperfield AR, Steele LW. Separation of the microvillous (maternal) from the basal (fetal) plasma membrane of human term placenta: methods and physiological significance of marker enzyme distribution. J Dev Physiol. 1979;1(5):361–377. [PubMed: 95548]
  187. Vanderpuye OA, Smith CH. Proteins of the apical and basal plasma membranes of the human placental syncytiotrophoblast: immunochemical and electrophoretic studies. Placenta. 1987;8(6):591–608.10.1016/0143-4004(87)90030-0. [PubMed: 3438256] [Cross Ref]
  188. Sawicki G, Radomski MW, Winkler-Lowen B, Krzymien A, Guilbert LJ. Polarized release of matrix metalloproteinase-2 and -9 from cultured human placental syncytiotrophoblasts. Biol Reprod. 2000;63:1390–1395.10.1095/biolreprod63.5.1390. [PubMed: 11058543] [Cross Ref]
  189. Wang Y, Gu Y, Lewis DF. Endothelial angiotensin II generation induced by placenta- derived factors from preeclampsia. Reprod Sci. 2008;15(9):932–938.10.1177/1933719108322432. [PMC free article: PMC3915510] [PubMed: 19050326] [Cross Ref]
  190. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992; 267(23): 16066–16068. [PubMed: 1644793]
  191. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Löffler BM, Müller M, Neidhart W and others. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365(6448):759–761.10.1038/365759a0. [PubMed: 8413655] [Cross Ref]
  192. Red-Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, Maltepe E, Okazaki K, Kochman R, Vo KC and others. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation. J Clin Invest. 2006;116(10): 2643–2652. [PMC free article: PMC1570373] [PubMed: 16998586]
  193. Red-Horse K. Lymphatic vessel dynamics in the uterine wall. Placenta. 2008;29(Suppl A):S55–59. [PMC free article: PMC2435487] [PubMed: 18155143]
  194. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone. 1996;18(2):125–132.10.1016/8756-3282(95)00457-2. [PubMed: 8833206] [Cross Ref]
  195. Bailey D, Baumal R, Law J, Sheldon K, Kannampuzha P, Stratis M, Kahn H, Marks A. Production of a monoclonal antibody specific for seminomas and dysgerminomas. Proc Natl Acad Sci U S A. 1986;83(14):5291–5295.10.1073/pnas.83.14.5291. [PMC free article: PMC323937] [PubMed: 3523489] [Cross Ref]
  196. Kaufmann P, Stark J, Stegner HE. The villous stroma of the human placenta. Cell Tissue Research. 1977;177(1):105–121.10.1007/BF00221122. [PubMed: 837398] [Cross Ref]
  197. Ordóñez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol. 2006(13):2:83–88. [PubMed: 16670463]
  198. Alexander JS, Gu Y, Zhao S, Sun J, Groome LJ, Wang Y. Lymphatic endothelial marker D2-40 is expressed in the placenta villous stroma and its expression is reduced in placentas from women with preeclampsia. Reprod Sci. 2010;17(3):118A.
  199. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174–1178.10.1056/NEJM198910263211707. [PubMed: 2571931] [Cross Ref]
  200. Gahrton G, Björkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med. 2000;248(3):185–201. [PubMed: 10971785]
  201. Lindvall O. Stem cells for cell therapy in Parkinson’s disease. Pharmacol Res. 2003;47(4): 279–287. [PubMed: 12644384]
  202. Goldman SA, Windrem MS. Cell replacement therapy in neurological disease. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1463–1475.10.1098/rstb.2006.1886. [PMC free article: PMC1664668] [PubMed: 16939969] [Cross Ref]
  203. Matikainen T, Laine J. Placenta—an alternative source of stem cells. Toxicol Appl Pharmacol. 2005;207(2 (Suppl)):544–549.10.1016/j.taap.2005.01.039. [PubMed: 15990135] [Cross Ref]
  204. Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, Holzgreve W, Surbek DV. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol. 2006;194: 664–673. [PubMed: 16522395]
  205. Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, Lanzoni G, Cantoni S, Cavallini C, Bianchi F and others. Term Amniotic membrane is a high throughout source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol. 2007;21(7):11. [PMC free article: PMC1810523] [PubMed: 17313666]
  206. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005;23(10):1549–1559.10.1634/stemcells.2004-0357. [PubMed: 16081662] [Cross Ref]
  207. Sakuragawa N, Kakinuma K, Kikuchi A, Okano H, Uchida S, Kamo I, Kobayashi M, Yokoyama Y. Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells. J Neurosci Res. 2004;78(2):208–214. [PubMed: 15378611]
  208. Chen LB, Jiang XB, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol. 2004;10(20):3016–3020. [PMC free article: PMC4576264] [PubMed: 15378785]
  209. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14(6):631–640.10.1016/j.bbmt.2008.01.006. [PubMed: 18489988] [Cross Ref]
  210. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;26(2):8. [PMC free article: PMC1215510] [PubMed: 16045800]
Copyright © 2010 by Morgan & Claypool Life Sciences.
Bookshelf ID: NBK53253


Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...